Longevity Pipeline
Loyal
Metabolic / IGF-1 reduction · Canine lifespan extension
Phase 3GLP-1 & the Incretin Boom
Mechanism
Metabolic / IGF-1 reduction
Intervention class
Small molecule
Indication
Canine lifespan extension
Stage
Phase 3
Evidence
animal
Funding
~$150M VC
Backers
Khosla, First Round, Bain
Overview
First company with an FDA pathway (Expanded Conditional Approval) toward a drug whose endpoint is lifespan. Dogs are the wedge; the regulatory precedent for 'aging as indication' is the prize.
Technology
Loyal works in GLP-1 & the Incretin Boom — The gut hormone that reset obesity — and is now eyeing aging itself.
Read the GLP-1 & the Incretin Boom brief →Related companies
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.